Education
About Us
Working with TipRanks
Follow Us
GeoVax Labs (GOVX)
NASDAQ:GOVX
Top Page
GeoVax Labs
(NASDAQ:GOVX)
Select Model
Select Model
Rating:34Underperform
Price Target:―
GeoVax Labs is navigating substantial financial and operational challenges, reflected in its low financial performance score. While there are positive developments in vaccine advancements and strategic partnerships, the negative impact of the BARDA contract termination and bearish technical indicators weigh heavily on the overall score.
Positive Factors
Vaccine Development Portfolio
GeoVax's robust vaccine development portfolio positions it to address unmet healthcare needs, potentially leading to expedited registration and market entry.
Strategic Partnerships
Strategic partnerships enhance GeoVax's global development and commercialization efforts, potentially increasing market reach and funding opportunities.
Cash Position
A strong cash position provides GeoVax with a buffer to manage operational expenses and invest in R&D, supporting long-term sustainability despite current challenges.
Negative Factors
BARDA Contract Termination
The BARDA contract termination poses a strategic setback, potentially affecting financial support and delaying vaccine development timelines.
Negative Cash Flow
Persistent negative cash flow highlights cash management challenges, necessitating reliance on external financing and raising concerns about financial sustainability.
Increased Expenses
Rising R&D and administrative expenses could strain financial resources, impacting profitability and necessitating careful cost management to ensure long-term viability.
GeoVax Labs (GOVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.04M
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)3.07
Revenue Growth8.52%
EPS Growth79.51%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.31
Shares Outstanding29,705,360
10 Day Avg. Volume1,123,459
30 Day Avg. Volume1,033,800
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.54
Price to Sales (P/S)3.24
P/FCF Ratio-0.52
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue3.04
Enterprise Value/Gross Profit3.09
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$12.00Price Target Upside2900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GeoVax Labs Business Overview & Revenue Model
Company DescriptionGeoVax Labs (GOVX) is a biotechnology company specializing in developing human vaccines. The company's primary focus is on creating vaccines for infectious diseases, cancer immunotherapy, and other novel treatments by utilizing their innovative MVA-VLP vaccine platform. GeoVax leverages its expertise in vaccine development to address global health challenges, aiming to provide solutions for diseases such as HIV, Zika, Lassa fever, Ebola, and COVID-19.
How the Company Makes MoneyGeoVax Labs generates revenue through a combination of government and non-governmental grants, collaborative research and development agreements, and potential licensing deals. The company partners with various organizations and institutions to advance its vaccine candidates, often receiving funding and milestone payments in return. GeoVax also seeks to monetize its vaccine platform through licensing agreements with other biotech or pharmaceutical companies, allowing them to use the technology for their own product development. Revenue may also be derived from future product sales as vaccines progress through clinical trials and achieve regulatory approval.
GeoVax Labs Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 26, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant advancements in the development and potential expedited approval of key vaccine candidates, along with increased industry interest and collaboration potential. However, financial challenges, including decreased revenue and increased net loss, present concerns. Overall, the positive development news is somewhat tempered by the financial performance.Q3-2025 Updates
Positive Updates
Expedited Development Path for GEO-MVA
GeoVax received guidance from the European Medicines Agency to bypass Phase I and Phase II trials for GEO-MVA, proceeding directly to a Phase III immuno-bridging trial, potentially accelerating marketing authorization and revenue generation.
Increased Interest in Partnerships and Funding
The company is experiencing increased interest in partnerships and collaborations from industry players and nondilutive funding organizations, particularly for GEO-MVA and GEO-CM04S1.
Progress in Vaccine Manufacturing Process
GeoVax is advancing its MVA vaccine manufacturing process, which is expected to provide a significant advantage in the production of MVA-based vaccines.
Significant Interest in GEO-CM04S1
GEO-CM04S1 is gaining recognition as a needed vaccine for immunocompromised adults, with ongoing clinical trials and discussions for potential partnerships.
Negative Updates
Revenue Decline
Revenues decreased to $2.5 million in the first nine months of 2025 compared to $3.1 million in 2024, primarily due to the termination of the BARDA Project NextGen contract.
Increased Net Loss
Net loss for the third quarter of 2025 was $6.3 million, up from $5.8 million in 2024, and $17 million for the year-to-date compared to $16.7 million in 2024.
R&D and G&A Expenses
Despite a decrease in R&D expenses due to the termination of the BARDA contract, there were higher personnel and administrative costs, contributing to overall financial challenges.
Company Guidance
During the GeoVax Third Quarter 2025 Corporate Update Call, the company provided several key metrics regarding its progress and strategic initiatives. GeoVax highlighted its vaccine candidate GEO-MVA, which received expedited development guidance from the European Medicines Agency (EMA) to bypass Phase I and Phase II trials and proceed directly to a Phase III immuno-bridging trial. This advancement could lead to earlier marketing authorization and revenue generation. Financially, for the nine months ended September 30, 2025, GeoVax reported revenues of $2.5 million, a decrease from $3.1 million in 2024, primarily due to the termination of the BARDA Project NextGen contract. Research and development expenses decreased to $15.1 million from $16.1 million in the previous year, while general and administrative expenses increased to $4.6 million from $3.8 million. The company's net loss for the quarter was $6.3 million, slightly higher than $5.8 million in 2024. GeoVax remains focused on advancing its GEO-MVA vaccine and other product candidates, with significant interest in partnerships and collaborations to support development and commercialization.GeoVax Labs Financial Statement Overview
Summary
GeoVax Labs faces significant financial challenges with no revenue growth and continuous net losses, reflecting operational and market difficulties. The company's strong cash position offsets some risks, but negative cash flows and reliance on financing indicate potential financial instability.Income Statement
GeoVax Labs has consistently reported zero or negligible revenue, indicating a significant challenge in generating sales. The company has experienced persistent net losses with negative EBIT and EBITDA margins, reflecting operational inefficiencies and high costs relative to its revenue base.10
Very Negative
Balance Sheet
The balance sheet shows a relatively strong cash position with no debt, which is a positive sign of financial prudence. However, the equity ratio is weak due to a low level of total assets and historical negative equity, posing risks to financial stability and growth potential.25
Negative
Cash Flow
GeoVax Labs exhibits negative operating and free cash flow, indicating potential cash management issues. The company relies heavily on financing activities to support its operations, raising concerns about sustainability and the need for continued external funding.15
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.35M | 3.95M | 0.00 | 81.53K | 385.50K | 1.82M |
| Gross Profit | 3.30M | 3.86M | -20.72M | -9.04M | 385.50K | 1.82M |
| EBITDA | -25.24M | -24.88M | -26.67M | -13.97M | -18.53M | -2.79M |
| Net Income | -25.31M | -24.99M | -25.97M | -14.02M | -18.57M | -2.96M |
Balance Sheet | ||||||
| Total Assets | 6.73M | 8.16M | 9.28M | 31.35M | 11.80M | 10.39M |
| Cash, Cash Equivalents and Short-Term Investments | 5.01M | 5.51M | 6.45M | 27.61M | 11.42M | 9.88M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 198.06K |
| Total Liabilities | 1.82M | 3.11M | 3.52M | 4.75M | 7.43M | 825.00K |
| Stockholders Equity | 4.91M | 5.05M | 5.76M | 26.60M | 4.36M | 9.57M |
Cash Flow | ||||||
| Free Cash Flow | -24.27M | -24.70M | -25.22M | -19.16M | -11.24M | -2.91M |
| Operating Cash Flow | -24.27M | -24.68M | -25.17M | -19.03M | -11.20M | -2.75M |
| Investing Cash Flow | -27.61K | -20.65K | -48.95K | -134.26K | -47.72K | -156.79K |
| Financing Cash Flow | 20.71M | 23.75M | 4.06M | 35.35M | 12.78M | 12.51M |
GeoVax Labs Technical Analysis
Negative
0.40
Price Trends
0.52
Negative
0.62
Negative
0.86
Negative
Market Momentum
-0.04
Negative
37.06
Neutral
17.35
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOVX, the sentiment is Negative. The current price of 0.4 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.52, and below the 200-day MA of 0.86, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 37.06 is Neutral, neither overbought nor oversold. The STOCH value of 17.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOVX.
GeoVax Labs Risk Analysis
GeoVax Labs disclosed 31 risk factors in its most recent earnings report. GeoVax Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GeoVax Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $15.14M | ― | -22.03% | ― | -41.76% | 87.36% | |
43 Neutral | $18.04M | ― | -32.92% | ― | -44.31% | -34.17% | |
41 Neutral | $16.26M | -0.58 | -119.92% | ― | -22.41% | 78.88% | |
39 Underperform | $14.83M | ― | -169.32% | ― | ― | 53.13% | |
35 Underperform | $11.96M | -1.28 | -69.64% | ― | ― | 22.63% | |
34 Underperform | $11.04M | -0.21 | -377.44% | ― | 8.52% | 79.51% |
* Healthcare Sector Average
GOVX
GeoVax Labs
0.40
-1.85
-82.22%
BLRX
Bioline RX Ltd Sponsored ADR
3.22
-7.58
-70.19%
SNGX
Soligenix
1.55
-1.60
-50.79%
LPCN
Lipocine
3.09
-1.82
-37.07%
EDSA
Edesa Biotech
1.72
-0.71
-29.22%
LGVN
Longeveron
0.64
-1.36
-68.00%
GeoVax Labs Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
GeoVax Labs Faces Contract Termination for COVID-19 Vaccine
Negative
Apr 14, 2025
On April 11, 2025, GeoVax Labs received a notification from Advanced Technology International to halt work on a Phase 2B clinical trial for their GEO-CM04S1 COVID-19 vaccine. The termination of the contract was decided by BARDA for governmental convenience, impacting the company’s ongoing project and possibly its strategic positioning in vaccine development.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
GeoVax Labs is navigating substantial financial and operational challenges. While the BARDA award and vaccine advancements are significant positives, the company’s financial instability, negative cash flow, and bearish technical indicators weigh heavily on its overall score. The mixed sentiment from the earnings call, highlighting both achievements and setbacks, contributes to a cautious outlook.
To see Spark’s full report on GOVX stock, click here.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.